AEterna Zentaris (AEZS) recently reported an abysmal Q1 earnings report that revealed the company only received $0.04 million in royalty revenue, which was a bit of a headscratcher seeing that the expected revenue was over $4 million. One would think there would be a strong sell-off when a company reports 1/100th of the forecasted revenue, but AEZS has been showing more of slow bleed rather than a flush. Overall, the share price has hovered over $3.00 since the company announced a European approval for its adult growth hormone deficiency "GHD" drug, Macrilen